Is Tesla Stock Overvalued or a Buy for the Next Decade?
Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…
Buy
75
PBE Quote, Financials, Valuation and Earnings
Last price:
$62.80
Seasonality move
:
4.95%
Day range:
$62.62 - $62.88
52-week range:
$54.52 - $72.84
Dividend yield:
0.07%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
6.4K
Avg. volume:
5.8K
1-year change:
-1.25%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
$62.97 | -- | -- | -- | $0.03 | 0.07% | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
$79.84 | -- | -- | -- | $0.27 | 1.14% | -- |
|
XBI
SPDR S&P Biotech ETF
|
$79.30 | -- | -- | -- | $0.01 | 0.17% | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
$82.32 | -- | -- | -- | $0.03 | 0.04% | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
$97.00 | -- | -- | -- | $0.04 | 0.33% | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
$40.17 | -- | -- | -- | $0.15 | 1.64% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 1.183 | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | 0.581 | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | 1.543 | -- | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
-- | 1.636 | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | 1.308 | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | 0.578 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
Invesco Biotechnology & Genome ETF vs. Competitors
-
Which has Higher Returns PBE or PJP?
Invesco Pharmaceuticals ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- -
What do Analysts Say About PBE or PJP?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than Invesco Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 PJPInvesco Pharmaceuticals ETF0 0 0 -
Is PBE or PJP More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.840, which suggesting that the stock is 15.98% less volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.530, suggesting its less volatile than the S&P 500 by 46.992%.
-
Which is a Better Dividend Stock PBE or PJP?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.07%. Invesco Pharmaceuticals ETF offers a yield of 1.14% to investors and pays a quarterly dividend of $0.27 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or PJP?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns PBE or XBI?
SPDR S&P Biotech ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat SPDR S&P Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- XBISPDR S&P Biotech ETF-- -- -- -
What do Analysts Say About PBE or XBI?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than SPDR S&P Biotech ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than SPDR S&P Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 XBISPDR S&P Biotech ETF0 0 0 -
Is PBE or XBI More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.840, which suggesting that the stock is 15.98% less volatile than S&P 500. In comparison SPDR S&P Biotech ETF has a beta of 0.976, suggesting its less volatile than the S&P 500 by 2.396%.
-
Which is a Better Dividend Stock PBE or XBI?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.07%. SPDR S&P Biotech ETF offers a yield of 0.17% to investors and pays a quarterly dividend of $0.01 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. SPDR S&P Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or XBI?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than SPDR S&P Biotech ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than SPDR S&P Biotech ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while SPDR S&P Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for SPDR S&P Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- XBISPDR S&P Biotech ETF-- -- -- --
-
Which has Higher Returns PBE or XHE?
SPDR S&P Health Care Equipment ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat SPDR S&P Health Care Equipment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- XHESPDR S&P Health Care Equipment ETF-- -- -- -
What do Analysts Say About PBE or XHE?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Health Care Equipment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than SPDR S&P Health Care Equipment ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than SPDR S&P Health Care Equipment ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 XHESPDR S&P Health Care Equipment ETF0 0 0 -
Is PBE or XHE More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.840, which suggesting that the stock is 15.98% less volatile than S&P 500. In comparison SPDR S&P Health Care Equipment ETF has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.861%.
-
Which is a Better Dividend Stock PBE or XHE?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.07%. SPDR S&P Health Care Equipment ETF offers a yield of 0.04% to investors and pays a quarterly dividend of $0.03 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. SPDR S&P Health Care Equipment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or XHE?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than SPDR S&P Health Care Equipment ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than SPDR S&P Health Care Equipment ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while SPDR S&P Health Care Equipment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for SPDR S&P Health Care Equipment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- XHESPDR S&P Health Care Equipment ETF-- -- -- --
-
Which has Higher Returns PBE or XHS?
SPDR S&P Health Care Services ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat SPDR S&P Health Care Services ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- XHSSPDR S&P Health Care Services ETF-- -- -- -
What do Analysts Say About PBE or XHS?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Health Care Services ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than SPDR S&P Health Care Services ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than SPDR S&P Health Care Services ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 XHSSPDR S&P Health Care Services ETF0 0 0 -
Is PBE or XHS More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.840, which suggesting that the stock is 15.98% less volatile than S&P 500. In comparison SPDR S&P Health Care Services ETF has a beta of 1.046, suggesting its more volatile than the S&P 500 by 4.633%.
-
Which is a Better Dividend Stock PBE or XHS?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.07%. SPDR S&P Health Care Services ETF offers a yield of 0.33% to investors and pays a quarterly dividend of $0.04 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. SPDR S&P Health Care Services ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or XHS?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than SPDR S&P Health Care Services ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than SPDR S&P Health Care Services ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while SPDR S&P Health Care Services ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for SPDR S&P Health Care Services ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- XHSSPDR S&P Health Care Services ETF-- -- -- --
-
Which has Higher Returns PBE or XPH?
SPDR S&P Pharmaceuticals ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat SPDR S&P Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- XPHSPDR S&P Pharmaceuticals ETF-- -- -- -
What do Analysts Say About PBE or XPH?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than SPDR S&P Pharmaceuticals ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than SPDR S&P Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 XPHSPDR S&P Pharmaceuticals ETF0 0 0 -
Is PBE or XPH More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.840, which suggesting that the stock is 15.98% less volatile than S&P 500. In comparison SPDR S&P Pharmaceuticals ETF has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.443%.
-
Which is a Better Dividend Stock PBE or XPH?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.07%. SPDR S&P Pharmaceuticals ETF offers a yield of 1.64% to investors and pays a quarterly dividend of $0.15 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. SPDR S&P Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or XPH?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than SPDR S&P Pharmaceuticals ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than SPDR S&P Pharmaceuticals ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while SPDR S&P Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for SPDR S&P Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- XPHSPDR S&P Pharmaceuticals ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Apple Stock Undervalued or Overvalued?
For many years, Apple (NASDAQ:AAPL) was just about the perfect…
Where Will Palo Alto Networks Stock Be in 5 Years?
You know those companies that just refuse to slow down…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
68
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
58
TNXP alert for May 28
Tonix Pharmaceuticals Holding [TNXP] is up 1.57% over the past day.
Sell
37
ATS alert for May 29
ATS [ATS] is down 1.27% over the past day.
Buy
88
SMR alert for May 28
NuScale Power [SMR] is down 0.37% over the past day.
